At a glance
ClinicalIndex Comparison RecordN/ACompleted· 101 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vascular Fingerprint to Identify Patients at Risk for Arterial Cardiovascular Events Within the First Year After Start of Cisplatin-based Chemotherapy for Testicular Cancer: a Validation Study
In Brief
An observational study for Testicular Cancer. Completed, enrolled 101 participants across 5 sites in 3 countries.
Detailed Summary
The vascular fingerprint is a simple selection tool to identify testicular cancer patients with a high risk of arterial cardiovascular events during and in the first year after cisplatin chemotherapy. Eventually, this selection method allows a relative small randomized intervention study with i.e. LMWH during chemotherapy to prove the effectiveness and safety in lowering the chance of an arterial cardiovascular event.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsTesticular Cancer
CountriesNetherlands, Portugal, Switzerland
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedOct 2015
Primary CompletionApr 2024
TodayJul 2026
First PostedOct 12, 2015
Enrollment StartOct 1, 2015
Primary CompletionApr 1, 2024
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 10.7 years ago